THE COMPANY/THE MISSION
Meissa Vaccines is on a mission to solve a puzzle that has eluded scientists for decades—a pediatric vaccine against respiratory syncytial virus, or RSV.
Making vaccines from a live virus is a balancing act between safety and immunogenicity that, if successful, can promote broad immunity that mimics natural immunity against the infecting agent.
Marty Moore, founder and CEO of Meissa Vaccines, talks more about Meissa’s platform technology, how it works, and why its approach could provide significant benefits over existing COVID-19 vaccines.
In the final feature of Big4Bio’s Company to Watch program for July, we asked Meissa Vaccines’ Board Chairperson Kenneth J. Kelley about his predictions for Meissa and the importance of the company’s efforts.